Tirzepatide in Texas: statewide telehealth access

What Texas law requires before anyone prescribes

Texas does not treat an online visit as a lesser visit. Chapter 111 of the Occupations Code and Chapter 174 of the Texas Administrative Code set the standard of care for telemedicine at the same level as in-person care and govern how a prescription may follow. The practical consequence is simple: a real evaluation happens first, or the encounter is not legitimate care.

Where you live inside Texas does not change that. Someone searching from Houston and someone searching from a town outside Lubbock go through the same intake, because the rule keys on patient location and clinician licensure, not on driving distance.

What the dual-agonist design actually means

Tirzepatide activates two incretin receptors, GLP-1 and GIP, where semaglutide activates one. Both slow gastric emptying and reduce appetite. The second pathway is the reason tirzepatide is discussed separately rather than as another semaglutide, and it is also part of why the side-effect conversation is not identical between the two.

Gastrointestinal effects remain the dominant adverse-reaction group for this class. Nausea, vomiting, diarrhea, and constipation cluster around dose increases. The labeled titration schedule exists to manage that, which is why stepping up faster than the label is not a shortcut.

• GLP-1 receptor: appetite and gastric-emptying effects shared with semaglutide
• GIP receptor: the second incretin pathway unique to tirzepatide among approved options
• Titration: stepwise by label, adjusted by a clinician rather than by the patient

What the trials reported

SURMOUNT-1 studied tirzepatide once weekly in adults with obesity and reported substantial mean weight reduction against placebo over 72 weeks. SURMOUNT-5 then compared tirzepatide directly with semaglutide in adults with obesity and reported greater mean reduction with tirzepatide.

Both numbers are population averages from controlled trials with structured follow-up. They describe what happened to groups, not what will happen to you, and they were produced in studies that included lifestyle counseling rather than medication alone. A clinician deciding between molecules is weighing your history, not a headline.

Heat, dehydration, and storage in a Texas climate

The class carries a warning that vomiting and diarrhea can cause dehydration and, in reported cases, acute kidney injury. Texas summers add fluid loss independent of the medication, so a dose increase during a stretch of extreme heat leaves less margin. That is worth raising at a follow-up rather than absorbing quietly.

Storage matters for the same reason. Labeled ranges assume refrigeration or a limited room-temperature window, and a closed vehicle exceeds both quickly. Read the storage section on the carton you actually received, since presentations differ.

What Beema offers Texas patients today

Beema Health is a cash-pay telehealth program for medical weight loss, available to adults in all 50 states including Texas. A licensed provider reviews intake and decides independently whether compounded semaglutide, compounded tirzepatide, or no medication is appropriate. Compounded tirzepatide is not FDA-approved and is considered only when legally available and clinically appropriate. Prescribing is never guaranteed.

Beema does not sell Zepbound or Mounjaro. Those brand names appear here because their prescribing information is the public source for labeled facts about tirzepatide. Current pricing lives on the tirzepatide program page, which is the authoritative source rather than any figure quoted in an article.

Where to read next

For the process rather than the geography, the tirzepatide online guide covers what a lawful telehealth path looks like. For Houston specifically, see tirzepatide in Houston. For the other molecule in Texas, see semaglutide in Texas. Live cash-pay plans: compounded tirzepatide.

Frequently asked questions

Sources

1. [1] Texas Occupations Code Chapter 111. Telemedicine and telehealth.
2. [2] Texas Administrative Code, Title 22, Part 9, Chapter 174: Telemedicine practice standards and prescribing.
3. [3] Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022.
4. [4] Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025.
5. [5] Zepbound (tirzepatide) prescribing information via DailyMed.
6. [6] U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss.